Thanks for stirring the pot. That often times is the best strategy for evaluating any biotech company, from any perspective. As some on this micro-modestly followed board know, I may have an opinion on all 4 pts above, esp on the science and clinical studies. But I will defer to others first, having formed some solid (read biased) opinions on many aspects of OMER.
Disclosure: I continue to hold a significant position in OMER, knowing this is a marathon, but now ready for a final sprint for Narso.
Also call me a strong believer in the role of SARS-nCoV-2 N-protein in activation of tissue specific pathology in COVID-19, particularly lung, kidney and possibly CNS. I have read all the complement animal model and clinical trial peer-reviewed literature relevant to medical treatment for COVID-19.